首页 / 院系成果 / 成果详情页

Intrathecal Morphine Infusion Therapy via a Percutaneous Port for Refractory Cancer Pain in China: An Efficacy, Safety and Cost Utilization Analysis

  • 作者:
    Qin, Wangjun[1] Li, Yifan[2] Liu, BoTao(刘波涛)[2] Liu, Ying[1] Zhang, Yi[2] Zhang, Xianglin[1] Li, Pengmei[1] Fan, BiFa(樊碧发)*[2]
  • 地址:

    [1]China Japan Friendship Hosp, Dept Pharm, Beijing, Peoples R China.

    [2]China Japan Friendship Hosp, Dept Pain Management, Beijing, Peoples R China.

  • 语种:
    英文
  • 期刊:
    JOURNAL OF PAIN RESEARCH ISSN:1178-7090 2020 年 13 卷 (231 - 237)
  • 收录:
  • 关键词:
  • 摘要:

    Purpose: Intrathecal morphine infusion therapy via a percutaneous port (IMITPP) has been used widely for its relatively low initial cost. However, there is scarce knowledge about IMITPP. In this study, we sought to evaluate efficacy, complications, and the interval required to achieve the cost equivalence of IMITPP in patients with refractory cancer pain in China.
    Patients and Methods: A retrospective chart review was conducted on cancer patients who had received IMITPP at our hospital between April 2017 and April 2019. Data from the numeric pain rating scale and Karnofsky performance scores, and complications and costs related to IMITPP were collected from medical records. Daily analgesic costs before and after IMITPP were calculated based on the doses of opioids on admission and at discharge, respectively. The doses of systemic opioids before IMITPP were stratified into very high doses [VHD, oral morphine equivalent dose (OMED) >599 mg/day], high doses (HD, 300 mg/day <= OMED <= 599 mg/day), and regular doses (RD, OMED < 300 mg/day).
    Results: Intrathecal morphine infusion therapy via a percutaneous port provided significant pain relief, but impaired activities of daily living in patients with refractory cancer pain. The commonly reported complications included nausea/vomiting and urinary retention, most of which were managed with symptomatic therapies. The median interval required to achieve cost equivalence was 11.44 months. The median intervals of VHD group and HD group were significantly shorter than that of RD group.
    Conclusion: Intrathecal morphine infusion therapy via a percutaneous port provided effective cancer pain management without causing serious complications. Patients with higher doses of systemic opioids would economically benefit from IMITPP in a shorter time.

    收起
  • 基金信息:
    Beijing Natural Science FoundationBeijing Natural Science Foundation [7154236]
  • 推荐引用方式
    GB/T 7714:
    Qin Wangjun,Li Yifan,Liu Botao, et al. Intrathecal Morphine Infusion Therapy via a Percutaneous Port for Refractory Cancer Pain in China: An Efficacy, Safety and Cost Utilization Analysis [J].JOURNAL OF PAIN RESEARCH,2020,13:231-237.
  • APA:
    Qin Wangjun,Li Yifan,Liu Botao,Liu Ying,&Fan Bifa.(2020).Intrathecal Morphine Infusion Therapy via a Percutaneous Port for Refractory Cancer Pain in China: An Efficacy, Safety and Cost Utilization Analysis .JOURNAL OF PAIN RESEARCH,13:231-237.
  • MLA:
    Qin Wangjun, et al. "Intrathecal Morphine Infusion Therapy via a Percutaneous Port for Refractory Cancer Pain in China: An Efficacy, Safety and Cost Utilization Analysis" .JOURNAL OF PAIN RESEARCH 13(2020):231-237.
  • 条目包含文件:
    文件类型:.pdf,文件大小:668.08 K
浏览次数:21 下载次数:0 原文链接
浏览次数:21
下载次数:0
打印次数:0